235 related articles for article (PubMed ID: 36052162)
1. A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate.
Lobba ARM; Alvarez-Flores MP; Fessel MR; Buri MV; Oliveira DS; Gomes RN; Cunegundes PS; DeOcesano-Pereira C; Cinel VD; Chudzinski-Tavassi AM
Front Mol Biosci; 2022; 9():936107. PubMed ID: 36052162
[TBL] [Abstract][Full Text] [Related]
2. Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates.
Chudzinski-Tavassi AM; Morais KL; Pacheco MT; Pasqualoto KF; de Souza JG
Biomed Pharmacother; 2016 Feb; 77():14-9. PubMed ID: 26796259
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional properties of the Kunitz-type and C-terminal domains of Amblyomin-X supporting its antitumor activity.
Morais KLP; Ciccone L; Stura E; Alvarez-Flores MP; Mourier G; Driessche MV; Sciani JM; Iqbal A; Kalil SP; Pereira GJ; Marques-Porto R; Cunegundes P; Juliano L; Servent D; Chudzinski-Tavassi AM
Front Mol Biosci; 2023; 10():1072751. PubMed ID: 36845546
[TBL] [Abstract][Full Text] [Related]
4. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
[TBL] [Abstract][Full Text] [Related]
5. Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
Pacheco MT; Berra CM; Morais KL; Sciani JM; Branco VG; Bosch RV; Chudzinski-Tavassi AM
PLoS One; 2014; 9(12):e111907. PubMed ID: 25479096
[TBL] [Abstract][Full Text] [Related]
6. Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.
Pacheco MT; Morais KL; Berra CM; Demasi M; Sciani JM; Branco VG; Bosch RV; Iqbal A; Chudzinski-Tavassi AM
Exp Cell Res; 2016 Jan; 340(2):248-58. PubMed ID: 26748183
[TBL] [Abstract][Full Text] [Related]
7. Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.
Morais KL; Pacheco MT; Berra CM; Bosch RV; Sciani JM; Chammas R; de Freitas Saito R; Iqbal A; Chudzinski-Tavassi AM
Mol Cell Biochem; 2016 Apr; 415(1-2):119-31. PubMed ID: 27015684
[TBL] [Abstract][Full Text] [Related]
8. Structural findings and molecular modeling approach of a TFPI-like inhibitor.
Pasqualoto KF; Balan A; Barreto SA; Simons SM; Chudzinski-Tavassi AM
Protein Pept Lett; 2014 May; 21(5):452-7. PubMed ID: 24330085
[TBL] [Abstract][Full Text] [Related]
9. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
de Souza JG; Morais KL; Anglés-Cano E; Boufleur P; de Mello ES; Maria DA; Origassa CS; de Campos Zampolli H; Câmara NO; Berra CM; Bosch RV; Chudzinski-Tavassi AM
Oncotarget; 2016 Sep; 7(38):62255-62266. PubMed ID: 27566592
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity.
Maria DA; Will SEAL; Bosch RV; Souza JG; Sciani JM; Goldfeder MB; Rondon GG; Chudzinski-Tavassi AM
Toxicol Rep; 2019; 6():51-63. PubMed ID: 30581760
[TBL] [Abstract][Full Text] [Related]
11. Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells.
Schmidt MCB; Morais KLP; Almeida MES; Iqbal A; Goldfeder MB; Chudzinski-Tavassi AM
Cell Adh Migr; 2020 Dec; 14(1):129-138. PubMed ID: 30238848
[TBL] [Abstract][Full Text] [Related]
12. Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis.
Francischetti IM; Mather TN; Ribeiro JM
Thromb Haemost; 2004 May; 91(5):886-98. PubMed ID: 15116248
[TBL] [Abstract][Full Text] [Related]
13. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.
Francischetti IM; Valenzuela JG; Andersen JF; Mather TN; Ribeiro JM
Blood; 2002 May; 99(10):3602-12. PubMed ID: 11986214
[TBL] [Abstract][Full Text] [Related]
14. Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis.
Drewes CC; Dias RY; Hebeda CB; Simons SM; Barreto SA; Ferreira JM; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2012 Sep; 60(3):333-40. PubMed ID: 22575283
[TBL] [Abstract][Full Text] [Related]
15. A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system.
Chudzinski-Tavassi AM; De-Sá-Júnior PL; Simons SM; Maria DA; de Souza Ventura J; Batista IF; Faria F; Durães E; Reis EM; Demasi M
Toxicon; 2010 Dec; 56(7):1145-54. PubMed ID: 20570593
[TBL] [Abstract][Full Text] [Related]
16.
De Paula VS; Silva FHS; Francischetti IMB; Monteiro RQ; Valente AP
Biomol NMR Assign; 2017 Oct; 11(2):293-296. PubMed ID: 28856584
[TBL] [Abstract][Full Text] [Related]
17. Identification and anticoagulant activity of a novel Kunitz-type protein HA11 from the salivary gland of the tick Hyalomma asiaticum.
Zhang H; Qiao R; Gong H; Cao J; Zhou Y; Zhou J
Exp Appl Acarol; 2017 Jan; 71(1):71-85. PubMed ID: 28091958
[TBL] [Abstract][Full Text] [Related]
18. Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro".
Akagi EM; Júnior PL; Simons SM; Bellini MH; Barreto SA; Chudzinski-Tavassi AM
Biomed Pharmacother; 2012 Feb; 66(1):64-9. PubMed ID: 22281290
[TBL] [Abstract][Full Text] [Related]
19.
Costa GCA; Ribeiro ICT; Melo-Junior O; Gontijo NF; Sant'Anna MRV; Pereira MH; Pessoa GCD; Koerich LB; Oliveira F; Valenzuela JG; Giunchetti RC; Fujiwara RT; Bartholomeu DC; Araujo RN
Front Immunol; 2020; 11():611104. PubMed ID: 33633731
[No Abstract] [Full Text] [Related]
20. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.
Maria DA; de Souza JG; Morais KL; Berra CM; Zampolli Hde C; Demasi M; Simons SM; de Freitas Saito R; Chammas R; Chudzinski-Tavassi AM
Invest New Drugs; 2013 Jun; 31(3):493-505. PubMed ID: 22975862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
